SEC Filings
Immuneering Taps Grant C. Bogle For Its Board As It Prepares For Commercialization
The former TESARO commercial chief oversaw ZEJULA's U.S. launch; Immuneering's lead cancer drug is still in clinical development.
Immuneering (IMRX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The former TESARO commercial chief oversaw ZEJULA's U.S. launch; Immuneering's lead cancer drug is still in clinical development.
Earnings
The drug developer says faster, bigger Phase 3 enrollment shortens its cash runway from 2029 to the fourth quarter of 2028.
Earnings
The drugmaker extends Phase 2 follow-up, targets cash into the fourth quarter of 2028 and says faster enrollment could pull in its mid-2028 readout.